Senior Vice President of Clinical Development and Chief Medical Officer · CRESCENT BIOPHARMA, INC. (CBIO)

Helen Thackray

A named executive officer of CRESCENT BIOPHARMA in every fiscal year CompBrief holds from FY2017 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,294,329

Salary $450,522Stock awards $0Bonus $218,700

FY2019: $1,300,722

2nd of 3 named executive officers at Crescent Biopharma by FY2020 total.

3 named officers on file for CRESCENT BIOPHARMA, FY2020

Helen Thackray’s pay file — $29

  • 4 fiscal years of pay, line by line
  • CBIO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CRESCENT BIOPHARMA’s whole pay program stands against its peers

  • CRESCENT BIOPHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CBIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 5, 2021 (DEF 14A).

Free

Get Helen Thackray’s full pay file as a PDF — free

More than this page: up to 10 years of Helen’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Helen Thackray compensation by year

CRESCENT BIOPHARMA Summary Compensation Table · all 4 fiscal years held
In US dollars, as CRESCENT BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020
Salary$412,300$424,700$437,400$450,522
Bonus$0$0$0$218,700
Stock awards$0$0$0$0
Option awards$320,250$1,007,250$696,000$409,200
Non-equity incentive$197,904$163,085$158,776$207,240
Pension and deferred compensation$0$0$0$0
All other$4,050$5,447$8,546$8,667
Total$934,504$1,600,482$1,300,722$1,294,329

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRESCENT BIOPHARMA, INC. DEF 14A filed April 5, 2021, accession 0001558370-21-003956, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CRESCENT BIOPHARMA, INC. filed document, accession 0001558370-21-003956. Every figure is read from that document and cited to the page and table it appears in. Filed April 5, 2021.

$935K
$1.6M
$1.3M
$1.3M
FY17
FY18
FY19
FY20
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option120,000—$4.72
Option1,562—$6.33
Option52,083—$10.59
Option20,312—$20.03

Per the Outstanding Equity Awards at Fiscal Year-End table in CRESCENT BIOPHARMA, INC.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

CRESCENT BIOPHARMA’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Rachel KingPresident and Chief Executive Officer$2,387,150
Helen Thackray · this pageSenior Vice President of Clinical Development and Chief Medical Officer$1,294,329
Brian HahnSenior Vice President and Chief Financial Officer$1,212,720

The full CRESCENT BIOPHARMA compensation record

free company brief

This page is one person within CRESCENT BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRESCENT BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Helen Thackray's compensation dossier · One-time report. No refunds.